IDiyas

For the Inventor, By the Inventor

Montville, NJ, United States of America

Michael John Girgis

USPTO Granted Patents = 10


 

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 35(Granted Patents)


Company Filing History:

goldMedal7 out of 3,923 
 
Novartis Ag
 patents
silverMedal3 out of 19 
 
Novartis Pharmaceuticals Corporation
 patents

Years Active: 2001-2023

where 'Filed Patents' based on already Granted Patents

10 patents (USPTO):
1. 11642329 - Amorphous solid form of compounds containing S—N-valeryl-N- {[2'-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2023-05-09),
2. 11096918 - Amorphous solid form of compounds containing S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2021-08-24),
3. 9388134 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2016-07-12),
4. 8877938 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2014-11-04),
5. 8829194 - Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid (2014-09-09),
6. 7572917 - Process for the manufacture of organic compounds (2009-08-11),
7. 7452999 - [object Object] (2008-11-18),
8. 6835838 - Process for the manufacture of organic compounds (2004-12-28),
9. 6740776 - Air oxidation of an aromatic aldehyde to an aromatic acid (2004-05-25),
10. 6271394 - Process for producing amino acid amides (2001-08-07),

Title: **The Innovative Contributions of Michael John Girgis**

Introduction

Michael John Girgis, an accomplished inventor based in Montville, NJ, has made significant strides in the field of pharmaceutical innovations. Holding a remarkable portfolio of 10 patents, he primarily focuses on developing compounds that offer therapeutic benefits for hypertension and heart failure.

Latest Patents

Among Michael Girgis's latest patents are inventive formulations that include an amorphous solid form of compounds containing the angiotensin receptor antagonist (ARB) valsartan and a neutral endopeptidase inhibitor (NEPi). These compounds, which comprise intricate molecular structures such as S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties with sodium cations, are specifically engineered for the treatment of hypertension and/or heart failure.

Career Highlights

Michael's professional journey includes significant tenures at renowned companies such as Novartis AG and Novartis Pharmaceuticals Corporation. His work has notably contributed to the advancement of therapeutic solutions in cardiovascular health, utilizing his deep understanding of compound structures.

Collaborations

Throughout his career, Michael has collaborated with notable professionals, including Mahavir Prashad and Bin Hu. These partnerships have fostered innovative approaches and enhanced research outcomes in the pharmaceutical arena.

Conclusion

Michael John Girgis stands out as an impactful inventor in the realm of pharmaceuticals, with a robust portfolio of patents that underline his commitment to improving health outcomes. His innovative contributions continue to pave the way for advancements in treating critical health conditions such as hypertension and heart failure.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…